Related Experiment Video
Updated: Jun 14, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Thrombocytosis associated with enoxaparin: A very rare cause in newborns
Alparslan Tonbul1, Nurdan Uras, Cuneyt Tayman
1Fatih University School of Medicine, Department of Pediatrics, Division of Neonatology, Ankara, Turkey.
Abstract:
Newborn infants are most vulnerable to the development of thrombosis because of the developing neonatal hemostatic system, perinatal risk factors and different types of medical conditions. Enoxaparin is the current anticoagulant of choice with advantages for the treatment of neonatal thrombosis. Thrombocytosis induced by enoxaparin has been reported as a rare adverse effect of this medication in adults. However, to our knowledge, in newborns there have been no reported cases to date of thrombocytosis induced by enoxaparin.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
